Elaine Castellanos - May 26, 2021 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
VP, Chief Accounting Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
May 26, 2021
Transactions value $
-$1,053,716
Form type
4
Date filed
5/27/2021, 06:15 PM
Next filing
Jun 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Conversion of derivative security +10K +68.75% 24.5K May 26, 2021 Direct F1
transaction RETA Class A common stock Sale -$1.25M -10K -40.74% $124.55 14.5K May 26, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right to buy) Options Exercise $0 -2.93K -100% $0.00* 0 May 26, 2021 Class B common stock 2.93K $11.00 Direct F1, F3
transaction RETA Employee Stock Option (right to buy) Options Exercise $0 -7.07K -26.17% $0.00 19.9K May 26, 2021 Class B common stock 7.07K $22.57 Direct F1, F4
transaction RETA Class B common stock Options Exercise $32.3K +2.93K $11.00 2.93K May 26, 2021 Class A common stock 2.93K Direct F1
transaction RETA Class B common stock Options Exercise $159K +7.07K +240.83% $22.57 10K May 26, 2021 Class A common stock 7.07K Direct F1
transaction RETA Class B common stock Conversion of derivative security -10K -100% 0 May 26, 2021 Class A common stock 10K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $124.36 to $124.95. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The options vested in sixteen equal quarterly installments beginning on August 25, 2016.
F4 The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date.